NEWS
Topline Results from PALM 007 Study of SIGA’s Tecovirimat in Treatment of Mpox Released
SIGA Technologies announced topline results from the PALM 007 clinical trial of tecovirimat for mpox treatment.
The study did not meet its primary endpointof statistically significant improvement in lesion resolution time.
However, meaningful improvements were observed in patients treated early(within 7 days of symptom onset) and those with severe disease (100+ skin lesions).
Tecovirimat demonstrated a safety profile comparable to placebo. Despite missing the primary endpoint, SIGA remains encouraged by the potential benefits for specific patient groups.
The company plans to analyze the data further and continue additional clinical trials to evaluate tecovirimat's efficacy in real-world settings.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1360Followers
79Following
9660Visitors
Follow
Space Dust : the headline makes it sound worse than the summary of the report.
Jaguar8 OP Space Dust : Yup